CBDNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Completion of Patient Enrollment for Study of Cannabidiol Lotion for Eczema Treatment

Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products, has completed patient enrollment in its upcoming clinical study of JW-100, its proprietary cannabidiol lotion formulation for the treatment of atopic dermatitis, or eczema. The study is designed to investigate the efficacy and safety of JW-100. JUPW enrolled 66 patients for the multi-center, double-blinded, placebo-controlled trial. Study participants will be randomly selected to receive one of three topical formulations, including a placebo, at least twice daily. Data from the study is expected in Q1 2021. “We are eager to see the results of this trial, and should JW-100 prove effective, we plan to use the data from this study to file an Investigational New Drug (‘IND’) application with the U.S. Food and Drug Administration,” said Jupiter CEO Brian John in the press release. “With the eczema market valued at more than $10 billion in 2020 and a high percentage of patients unsatisfied with their current treatments, we believe Jupiter will be well-positioned to capitalize on the opportunity with our CBD-based proprietary formulation.”

To view the full press release, visit https://cnw.fm/vaHEW

About Jupiter Wellness Inc.

Jupiter Wellness is a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced, skin-care therapeutics address indications including eczema, burns, herpes cold sores and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skin-care products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For additional information about this company, please visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://cnw.fm/JUPW

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s